# 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

> **NCT04050215** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 937 (actual)

## Conditions studied

- Biochemically Recurrent Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Prostate Carcinoma
- PSA Level Greater Than Fifty
- PSA Progression
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Computed Tomography
- **DRUG:** Gallium Ga 68-labeled PSMA-11
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04050215
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-02
- **Primary completion:** 2021-09-27
- **Final completion:** 2021-09-27
- **Target enrollment:** 937 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04050215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04050215, "68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04050215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*